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• Medical devices that fail 
• Treating every patient the same
• Increasing costs
• Increasing patients
• Reactionary versus predictive
• And the list goes on…
What is the answer ?
15 Years Ago We Turned to Nanomedicine 
for Some Answers
Nanotechnology: The use of materials whose 
components exhibit significantly changed properties 
by gaining control of structures at the atomic, 
molecular, and supramolecular levels. 
Nanomedicine: Applications of nanotechnology in 
medicine.
Why Use Nanotechnology 
In Medicine ????
Nano-structured 
Medical Materials  
Compared to today’s implant
materials, nano-structured materials 
possess enhanced:







properties that may improve 
existing biomedical implant
applications.









































Initial Protein Coatings on Biomaterials
Control Everything
Create nano-surfaces


































Challenge #1: We need to 
establish more quantitative 
models to predict material-
protein interactions that control 
cell behavior. 
Challenge #2: Do not give up on 
“old” materials, there are ways 
to modify them to make them 
“new” and obtain quick
FDA approval
The following are projects which 
have all received FDA approval
with significant help from 
start-up companies……..
Commercialized by Nanovis, LLC
Anodized Titanium
Sketch map of anodization system
PROCEDURES:
Pretreatment: chemical 
polishing using  HF/HNO3 
mixture




Clean: acetone and ethanol
Sterilize
Anodized Ti Nanotubular Screws
Ti Screw Insertion
Anodized Titanium Amputee Rat Model
Rat Walking on Anodized Titanium Implant 
as Soon as 3 Days After Surgery




this as a pedical screw
Challenge #3: We have an 
infection problem. 
We need more biomaterial 
approaches that (without 
antibiotics) can inhibit bacteria 




Nanorough Silicon Nitride Smooth Silicon Nitride
Titanium PEEK
Silicon Nitride: 3 Months (bacteria innoculation)
Silicon Nitride  (nano-rough)  –
41% bone-implant interface
0% bacteria-implant interface
42%  of new bone growth in surgical area




26%  of new bone growth in surgical area




21%  of new bone growth in surgical area
88%  of bacteria growth in surgical area
Silicon Nitride (smooth) –
15% bone-implant interface
10% bacteria-implant interface
29%  of new bone growth in surgical area
10%  of bacteria growth in surgical area
Rat calvaria
model
Commercialized by Tyber Medical:
Nanostructured Orthopedic Coatings
Previous studies










SEM images of the Ti surfaces coated with (a)170 
nm, (b) 150 nm, (c) 130 nm, (d)110 nm 
hydroxyapatite powders, (e) plasma sprayed micron 






































































* P<0.01 compared with plasma-sprayed-deposited hydroxyapatite on Ti; ** P<0.01 compared with Ti 



































































































* P<0.01 compared with Ti (control); ** P<0.01 compared with plasma-sprayed-deposited 
hydroxyapatite on Ti
Ampicillin resistant E. coli
Another FDA approved 
nanotechnology process…..
Atomic Layer Depositions
• ALD TiO2 at 190
oC, 160oC, 120oC, 100nm thick
– Crystallinity is temperature dependent: Amorphous < 140oC, degree 
of crystallinity (anatase) increasing with temperature
– Morphology is temperature dependent
– Tg of PEEK is 143
oC – adhesion of ALD film to PEEK is likely to 
be affected by temperature relative to Tg
– Thick (~ 100nm) film allows development of crystal structure









Strong dependence on temperature indicating densification/high 































Osteoblast adhesion on Ti samples with 
different TiO2 coatings. 
Data represents mean ± SD. 
Osteoblast proliferation on Ti samples with 
different TiO2 coatings after 7 days. n=3.
Data represents mean ± SD.  
Osteoblast density increases on Ti


























































Osteoblast adhesion on PEEK samples with 
different TiO2 coatings. n=3
Data represents mean ± SD. 
Osteoblast proliferation on PEEK samples with 
different TiO2 coatings after 7 days. n=3




























Osteoblast density increases on
PEEK samples coated with Ti using
ALD
Thinking ahead ….. 
• Aren’t these approaches still 
reactionary ?
• Won’t the cost of healthcare continue 
to rise if we simply respond to health 
problems rather than predict them ?
• Won’t this problem continue to get 
worse with greater patient numbers ?
Challenge #4: We need 
implantable sensors to create 
more personalized medicine. 
Detecting in real time: 
• Serum proteins and disease marker proteins.
• Virus and pathogens
• Genomic DNA
Responding in real time: 
• Controllable drug delivery system











- Externally Controlled 
System 





Human Interface Molecular and Cellular Interaction
Molecular and Cellular Interaction
Current Sensors Used in Medicine:
Not at all Like our Immune System




We need sensors that behave 
more like our immune system.
(The next projects have not been approved by 
the FDA)
Basic Components of a Closed-Loop Sensing and 
Drug Administration
Real-time Detection of Proteins using Sensors and Releasing 





200 nm 200 nm
1 µm 100 nm
CNTs grown from the nanotubes of anodized Ti without a cobalt catalyst using 






CNTs grown from the nanotubes of anodized Ti surface with a cobalt catalyst using CVD 
for 20 min and 1 hr.







nanotubes grown out of 
anodized titanium 
(MWCNT-Ti)
15 µm 20 µm
3 µm 3 µm 3 µm
This sensor improves bone growth without even sensing
Results: Our Sensor
Next Generation of Sensors 














Same approach and sensors can be used on medical device surfaces and 
outside the body: Does not have to be a synthetic cell but 
nanotechnology needs to be involved.
Next Generation of Sensors 














Same approach and sensors can be used on medical device surfaces and 
outside the body: Does not have to be a synthetic cell but 
nanotechnology needs to be involved.
Synthetic Immune Nanoparticles
Scale Bars = 100nm
Geilich BM, et. al. Nanoscale. 7 (2015) 3511-3519
• Our version of medicine must transition to 
predictive not reactionary. 
• Our version of medicine must treat individuals not 
generalize for population or age groups.
• Our version of medicine must be dynamic not 
static.
• Unless we change, our version of medicine today 
is unlikely to create treatments for all diseases for 
all people that last a lifetime.
My Dream for the Future of 
Healthcare
Angstrom Medica and Spire Biomedical
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National Science Foundation
Integrated Graduate Education and Research Training Fellowship (IGERT),
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